Product Name :
Liarozole
Description:
Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties.
CAS:
115575-11-6
Molecular Weight:
308.76
Formula:
C17H13ClN4
Chemical Name:
6-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-1,3-benzodiazole
Smiles :
ClC1=CC(=CC=C1)C(C1=CC2NC=NC=2C=C1)N1C=NC=C1
InChiKey:
UGFHIPBXIWJXNA-UHFFFAOYSA-N
InChi :
InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid.{{Orteronel} web|{Orteronel} Cytochrome P450|{Orteronel} Protocol|{Orteronel} References|{Orteronel} custom synthesis|{Orteronel} Autophagy} Liarozole shows antitumoral properties.{{Fluvoxamine} web|{Fluvoxamine} Neuronal Signaling|{Fluvoxamine} Purity & Documentation|{Fluvoxamine} Formula|{Fluvoxamine} manufacturer|{Fluvoxamine} Cancer} |Product information|CAS Number: 115575-11-6|Molecular Weight: 308.PMID:23715856 76|Formula: C17H13ClN4|Chemical Name: 6-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-1,3-benzodiazole|Smiles: ClC1=CC(=CC=C1)C(C1=CC2NC=NC=2C=C1)N1C=NC=C1|InChiKey: UGFHIPBXIWJXNA-UHFFFAOYSA-N|InChi: InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Liarozole (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation. Liarozole (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis.|In Vivo:|Liarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation. Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially.|Products are for research use only. Not for human use.|